Journals / Zeynep Kamil medical journal (Online) / 2022 / Cilt: 53 - Sayı: 1

Ultrasound-guided liver mass biopsy

Pages
32–36
Publication Date
2022-10-12
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: An ultrasound-guided liver mass biopsy is a safe and effective method because of low complication rates and adequate tissue sampling.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: This study aimed to present the histopathological results and demographic characteristics of patients who underwent an ultrasound-guided liver mass biopsy.
📊
Key Findings & Data:Material and Methods: Medical information of patients who underwent a liver mass biopsy in the interventional radiology clinic between September 2016 and Septem- ber 2021 were retrieved retrospectively from the hospital data processing system and the interventional radiology archive.
💡
Conclusion & Impact:Conclusion: An ultrasound-guided liver mass biopsy is a safe and effective method because of low complication rates and adequate tissue sampling.
🔬Design:Research Article
📍Scope:2016 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: This study aimed to present the histopathological results and demographic characteristics of patients who underwent an ultrasound-guided liver mass biopsy. Material and Methods: Medical information of patients who underwent a liver mass biopsy in the interventional radiology clinic between September 2016 and Septem- ber 2021 were retrieved retrospectively from the hospital data processing system and the interventional radiology archive. Baseline demographic characteristics of the patients and the technical success and the complication rate of the biopsy pro- cedure were investigated. Results: A total of 283 liver mass biopsies were performed on 162 women and 121 men, with a mean age of 52.3 years. All biopsies were performed under ultrasound guidance with an 18 gauge fully-automatic Tru-Cut biopsy needle. After the biopsy, the histopathological diagnosis was malignant in 95.4% (n=270) and benign in 4.5% (n=13) of the masses. The most common malignant diagnosis was breast cancer metastasis (25.8%) and the most common benign diagnosis were cirrhotic nodule (1.4%) and granulomatous inflammation (1.4%). The technical success rate was 100% in this study. The most common complications were a subcapsular hematoma (n=5) and pain (n=2). There was a significant relationship between subcapsular hematoma formation and the histopathological diagnosis (p<0.05). The subcapsular hematoma was more common in patients with hepatocellular cancer and cirrhotic nodules. No massive bleeding, pneumothorax, or death occurred. Conclusion: An ultrasound-guided liver mass biopsy is a safe and effective method because of low complication rates and adequate tissue sampling.

🔖

Cite This Article

ONAY, M., BİNBOĞA, A. B. (2022). Ultrasound-guided liver mass biopsy. Zeynep Kamil medical journal (Online), Cilt: 53 - Sayı: 1, 32–36. https://ajindex.com/articles/426121

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Matos AP, Velloni F, Ramalho M, AlObaidy M, Rajapaksha A, Semelka RC. Focal liver lesions: Practical magnetic resonance imaging ap- proach. World J Hepatol 2015;7:1987–2008
  2. Galea N, Cantisani V, Taouli B. Liver lesion detection and character- ization: Role of diffusion-weighted imaging. J Magn Reson Imaging 2013;37:1260–76
  3. Oldhafer KJ, Habbel V, Horling K, Makridis G, Wagner KC. Benign liver tumors. Visc Med 2020;36:292–303
  4. Semelka RC, Cance WG, Marcos HB, Mauro MA. Liver metastases: Comparison of current MR techniques and spiral CT during arterial portography for detection in 20 surgically staged cases. Radiology 1999;213:86–91
  5. Namasivayam S, Martin DR, Saini S. Imaging of liver metastases: MRI. Cancer Imaging 2007;7:2–9
  6. Khalifa A, Rockey DC. The utility of liver biopsy in 2020. Curr Opin Gas- troenterol 2020;36:184–91
  7. Neuberger J, Patel J, Caldwell H, Davies S, Hebditch V, Hollywood C, et al. Guidelines on the use of liver biopsy in clinical practice from the British Society of Gastroenterology, the Royal College of Radiologists and the Royal College of Pathology. Gut 2020;69:1382–403
  8. Veltri A, Bargellini I, Giorgi L, Almeida PAMS, Akhan O. CIRSE guide- lines on percutaneous needle biopsy (PNB). Cardiovasc Intervent Ra- diol 2017;40:1501–13
  9. Feng RM, Zong YN, Cao SM, Xu RH. Current cancer situation in China: Good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond) 2019;39:22
  10. Patel IJ, Davidson JC, Nikolic B, Salazar GM, Schwartzberg MS, Walker TG, et al. Consensus guidelines for periprocedural management of co- agulation status and hemostasis risk in percutaneous image-guided in- terventions. J Vasc Interv Radiol 2012;23:727–36
  11. Choi JY, Lee JM, Sirlin CB. CT and MR imaging diagnosis and staging of hepatocellular carcinoma: Part I. Development, growth, and spread: Key pathologic and imaging aspects. Radiology 2014;272:635–54
  12. McGlynn KA, Tarone RE, El-Serag HB. A comparison of trends in the incidence of hepatocellular carcinoma and intrahepatic cholangio- carcinoma in the United States. Cancer Epidemiol Biomarkers Prev 2006;15:1198–203
  13. Chen VL, Sharma P. Role of biomarkers and biopsy in hepatocellular carcinoma. Clin Liver Dis 2020;24:577–90
  14. Tsilimigras DI, Brodt P, Clavien PA, Muschel RJ, D’Angelica MI, Endo I, et al. Liver metastases. Nat Rev Dis Primers 2021;7:27
  15. Siegel RL, Miller KD, Goding Sauer A, Fedewa SA, Butterly LF, An- derson JC, et al. Colorectal cancer statis